VALUATION HIGHLIGHTS

1. Oncology constitutes 39% of the Trefis price estimate for Pfizer's stock.
2. Primary Care constitutes 33% of the Trefis price estimate for Pfizer's stock.
3. Specialty Care constitutes 26% of the Trefis price estimate for Pfizer's stock.

WHAT HAS CHANGED?

Latest Earnings: Q4 and Full Year 2025

Pfizer reported full-year 2025 revenue of $61.5 billion, representing an operational increase of 5% compared to the prior year when excluding COVID-19 products. Adjusted diluted EPS for the full year was $2.85, an increase of 55% over 2024, driven primarily by significant cost-cutting initiatives and the integration of Seagen. Revenue growth was supported by strong performance in the oncology portfolio, which offset the continued and expected decline in Comirnaty and Paxlovid sales.

Note: Pfizer's FY'25 ended on December 31, 2025.

Oncology Portfolio Expansion via Seagen Integration

Pfizer has successfully integrated Seagen, significantly expanding its oncology pipeline and doubling its ADC (antibody-drug conjugate) resources. This strategic pivot is central to Pfizer's goal of delivering eight or more blockbuster oncology drugs by 2030. The company recently received regulatory approvals for several new indications in bladder and genitourinary cancers, which are expected to contribute incremental revenue starting in the first half of 2026 as the commercial rollout scales globally.

POTENTIAL UPSIDE & DOWNSIDE TO TREFIS PRICE

Below are key drivers of Pfizer's value that present opportunities for upside or downside to the current Trefis price estimate:

Specialty Care and Oncology

• Non-COVID Portfolio Growth: Revenue from the non-COVID product portfolio grew 7% operationally in the most recent fiscal year. Trefis estimates suggest mid-single-digit growth will continue, but successful Phase 3 readouts for late-stage pipeline assets could provide a 10% upside to long-term valuation if market share in the obesity or respiratory syncytial virus (RSV) markets exceeds expectations.


• Manufacturing Cost Realization: Pfizer achieved $4 billion in net cost savings through its middle-term realignment program. If the company maintains current operating margins despite inflationary pressures on raw materials, there is a potential for a 150 basis point improvement in adjusted EBITDA margins relative to current Trefis projections.

For additional details, select a division from the interactive Trefis split for Pfizer at the top of the page.

BUSINESS SUMMARY

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and distributes medicines and vaccines worldwide. Its business model focuses on high-margin innovative health products across therapeutic areas including oncology, immunology, cardiology, and rare diseases, while transitioning away from its pandemic-era reliance on COVID-19 countermeasures toward a diversified specialty medicine portfolio.

SOURCES OF VALUE

Pfizer's value is primarily derived from its robust R&D engine and its ability to commercialize large-scale therapeutic platforms across global markets.

Oncology Leadership and ADC Platform

The acquisition of Seagen has positioned Pfizer as a dominant player in the ADC market, a high-growth segment of cancer treatment. By combining Seagen's protein engineering with Pfizer's scale, the company now possesses one of the largest oncology pipelines in the industry, targeting a market expected to grow at a double-digit CAGR through 2030.

Deep Pipeline and Regulatory Expertise

Pfizer maintains a competitive moat through its extensive clinical trial infrastructure and historical success rate with the FDA. The company currently has over 30 programs in Phase 3 development, providing a consistent "ladder" of new product launches that mitigates the impact of upcoming patent expirations on older legacy brands.

KEY TRENDS

Shift Toward Precision Medicine and ADCs

The pharmaceutical industry is moving away from broad-spectrum treatments toward precision medicine. Pfizer's heavy investment in ADCs and mRNA technology aligns with this trend, allowing for targeted therapies that offer better patient outcomes and higher pricing power compared to traditional chemotherapy or small-molecule generics.

Aggressive Operational Efficiency Program

Following the post-pandemic decline in vaccine demand, Pfizer has shifted its strategy toward "lean" operations. The company is currently executing a multi-year cost realignment initiative designed to right-size its manufacturing footprint and reduce SG&A expenses, aiming to restore pre-pandemic profit margins by the end of 2027.